It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for Arbutus Biopharma Corporation (ABUS) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.03, or -1.18%, to $2.51. The Arbutus Biopharma Corporation has recorded 4,919 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that Arbutus to Present at JMP Securities Life Sciences Conference.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Arbutus Biopharma Corporation is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $2.54 and fluctuated between $2.5800 as its day high and $2.5200 as its day low. The current market capitalization of Arbutus Biopharma Corporation is $425.30M. A total of 0.66 million shares were traded on the day, compared to an average of 953.42K shares.
Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, ABUS has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 10 BUYs and 0 SELLs from insiders. Insiders purchased 1,062,200 shares during that period but sold 0.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for ABUS in the last 3 months, the mean price target is $5.40 with high estimates of $6.00 and low estimates of $4.00. In terms of 52-week highs and lows, ABUS has a high of $3.14 and a low of $1.85.
As of this writing, ABUS has an earnings estimate of -$0.11 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of -$0.1 per share and a lower estimate of -$0.13. The company reported an EPS of -$0.14 in the last quarter, which was -7.70% lower than expectations of -$0.13.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. ABUS’s latest balance sheet shows that the firm has $155.32M in Cash & Short Term Investments as of fiscal 2021. There were $2.61M in debt and $11.22M in liabilities at the time. Its Book Value Per Share was $0.89, while its Total Shareholder’s Equity was $169.44M.
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ABUS is Buy with a score of 5.00.